With efficacy assured, Merck halts another trial of blockbuster-to-be Winrevair

Merck has halted the phase 3 HYPERION trial of its pulmonary arterial hypertension (PAH) treatment Winrevair after reviewing positive interim results from another study and evaluating the drug’s overall clinical program.